MedTrace Logo

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

NCT04604613 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 518

Last updated 2026-03-09

No results posted yet for this study

Summary

This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to remove the uterus and/or cervix (hysterectomy). Having sentinel lymph node mapping performed may help researchers to see if the cancer has spread in patients with low risk endometrial cancer.

Conditions

  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions

PROCEDURE

Bilateral Salpingectomy with Oophorectomy

Undergo standard of care bilateral salpingo-oophorectomy

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

PROCEDURE

Hysterectomy

Undergo standard of care hysterectomy

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Lymph Node Mapping

Undergo sentinel lymph node mapping

PROCEDURE

Sentinel Lymph Node Biopsy

Undergo sentinel lymph node biopsy

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Shannon N Westin · M.D. Anderson Cancer Center

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-08
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604613 on ClinicalTrials.gov